Phaseline

Targets › EV71

EV71: drug programs, companies and trials

1 program from 1 company in 1 trial: 1 Phase 3; Infectious disease; next expected readout Nov 2026.

Open in Phaseline: the race on EV71, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Sinovac Biotechbivalent enterovirus vaccine (Vero cell), inactivated
inactivated bivalent enterovirus vaccine targeting Enterovirus 71 and Coxsackievirus A16
EV71, CA16Phase 3Hand, Foot, and Mouth Disease(HFMD)Nov 2026

Conditions

Hand, Foot, and Mouth Disease(HFMD) (1)

Modalities

other (1)

Companies

Sinovac Biotech (1)

Related targets

CA16 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.